HUP0300965A2 - Új aril-etén-szulfonamidok pirimidinszármazékai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents

Új aril-etén-szulfonamidok pirimidinszármazékai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk

Info

Publication number
HUP0300965A2
HUP0300965A2 HU0300965A HUP0300965A HUP0300965A2 HU P0300965 A2 HUP0300965 A2 HU P0300965A2 HU 0300965 A HU0300965 A HU 0300965A HU P0300965 A HUP0300965 A HU P0300965A HU P0300965 A2 HUP0300965 A2 HU P0300965A2
Authority
HU
Hungary
Prior art keywords
alkyl
heterocyclyl
amino
group
aryl
Prior art date
Application number
HU0300965A
Other languages
English (en)
Inventor
Martin Bolli
Christoph Boss
Martine Clozel
Walter Fischli
Thomas Weller
Original Assignee
Actelion Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd. filed Critical Actelion Pharmaceuticals Ltd.
Publication of HUP0300965A2 publication Critical patent/HUP0300965A2/hu
Publication of HUP0300965A3 publication Critical patent/HUP0300965A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A találmány (I) általános képletű aril-etén-szulfonamidokra és azokgyógyászatilag alkalmazható sóira vonatkozik - a képletben R1 és R2egymástól függetlenül aril- vagy heteroaril-csoportot jelent; R3jelentése fenilcsoport, mono-, di- vagy triszubsztituált fenilcsoport,arilcsoport vagy heteroaril-csoport; R4 jelentése hidrogénatom,halogénatom vagy trifluor-metil-alkil-, alkil-amino-, alkoxi-, alkil-szulfono-, alkil-szulfinil-, alkil-tio-, alkil-tio-alkil-, hidroxi-alkil-, alkoxi-alkil-, hidroxi-alkoxi-alkil-, hidroxi-alkil-amino-,alkil-amino-alkil-, amino-, di-alkil-amino-,[N-(hidroxi-alkil)-N-alkil]-amino-, aril-, aril-amino-, aril-alkil-amino-, aril-tio-, aril-alkil-tio-, aril-oxi-, aril-alkil-oxi-, aril-alkil-, aril-szulfinil-,heteroaril-, heteroaril-oxi-, heteroaril-alkil-oxi-, heteroaril-amino-, heteroaril-alkil-amino-, heteroaril-tio-, heteroaril-alkil-tio-, heteroaril-alkil-, heteroaril-szulfinil-, heterociklil-,heterociklil-alkil-oxi-, heterociklil-oxi-, heterociklil-amino-,heterociklil-alkil-amino-, heterociklil-tio-, heterociklil-alkil-tio-,heterociklil-alkil-, heterociklil-szulfinil-, cikloalkil-, cikloalkil-oxi-, cikloalkil-alkil-oxi-, cikloalkil-amino-, cikloalkil-alkil-amino-, cikloalkil-tio-, cikloalkil-alkil-tio-, cikloalkil-alkil- vagycikloalkil-szulfinil-csoport; R5 és R6 egymástól függetlenülhidrogénatomot vagy alkilcsoportot jelent; X vegyértékkötést vagy -O-,-S-, -NH- vagy -CH2- csoportot jelent; Y -O-, -S- vagy -NH- csoportotjelent; Z vegyértékkötést vagy -O-, -S- vagy -NH- csoportot jelent; ésQ jelentése -(CH2)n-, -CH2-ciklopropilén-CH2- vagy -(CH2)m-C<C-(CH2)p- csoport. A találmány kiterjed a vegyületeket tartalmazógyógyszerkészítményekre és a vegyületek alkalmazásáragyógyszerkészítmények előállítására. Ó
HU0300965A 2000-07-21 2001-07-10 Novel pyrimidin derivatives of arylethene sulfonamides, pharmaceutical compositions containing them and their use HUP0300965A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0007006 2000-07-21
PCT/EP2001/007922 WO2002008200A2 (en) 2000-07-21 2001-07-10 Arylethene-sulfonamides, their preparation and their use as endothelin antagonists

Publications (2)

Publication Number Publication Date
HUP0300965A2 true HUP0300965A2 (hu) 2003-10-28
HUP0300965A3 HUP0300965A3 (en) 2004-01-28

Family

ID=8164031

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300965A HUP0300965A3 (en) 2000-07-21 2001-07-10 Novel pyrimidin derivatives of arylethene sulfonamides, pharmaceutical compositions containing them and their use

Country Status (21)

Country Link
US (1) US6951856B2 (hu)
EP (1) EP1309564B1 (hu)
JP (1) JP4832706B2 (hu)
KR (1) KR100826332B1 (hu)
CN (1) CN100562518C (hu)
AR (1) AR030247A1 (hu)
AT (1) ATE329908T1 (hu)
AU (2) AU2001281970B2 (hu)
BR (1) BR0112614A (hu)
CA (1) CA2416785C (hu)
DE (1) DE60120711T2 (hu)
ES (1) ES2266233T3 (hu)
HU (1) HUP0300965A3 (hu)
IL (2) IL153471A0 (hu)
MX (1) MXPA03000430A (hu)
MY (1) MY140724A (hu)
NO (1) NO324771B1 (hu)
NZ (1) NZ523304A (hu)
TW (1) TWI289553B (hu)
WO (1) WO2002008200A2 (hu)
ZA (1) ZA200300137B (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0508461B8 (pt) 2004-03-05 2021-05-25 Hoffmann La Roche diaminopirimidinas, seus usos, e composição farmacêutica
EP1924564B1 (en) 2005-09-01 2016-11-09 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
EP1924566B1 (en) 2005-09-01 2016-01-13 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
KR101025381B1 (ko) 2005-09-01 2011-03-28 에프. 호프만-라 로슈 아게 Ｐ2ｘ3 및 ｐ2ｘ2/3 조정자로서의 다이아미노피리미딘
TWI331523B (en) * 2005-12-08 2010-10-11 Nat Health Research Institutes Vinylsulfonate compounds
WO2009020579A1 (en) * 2007-08-07 2009-02-12 Schering Corporation Gamma secretase modulators
WO2009104152A1 (en) * 2008-02-20 2009-08-27 Actelion Pharmaceuticals Ltd Combination treatment for ovarian cancer
IT1393136B1 (it) * 2009-03-11 2012-04-11 Sifa Vitor S R L Procedimento per la preparazione del bosentan
US20100256371A1 (en) * 2009-04-02 2010-10-07 Glenmark Processes for the preparation of bosentan and its intermediates thereof
AU2018332634A1 (en) * 2017-09-12 2020-04-30 Agency For Science, Technology And Research Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase
CN110885328B (zh) * 2018-09-10 2022-08-12 成都康弘药业集团股份有限公司 作为钠通道阻滞剂的磺酰胺类化合物及其用途
TWI833430B (zh) 2021-11-08 2024-02-21 大陸商正大天晴藥業集團股份有限公司 氮雜聯苯類化合物及其應用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW287160B (hu) * 1992-12-10 1996-10-01 Hoffmann La Roche
TW394761B (en) 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
JP2790065B2 (ja) * 1993-12-17 1998-08-27 田辺製薬株式会社 ベンゼンスルホンアミド誘導体及びその製法
IL111959A (en) * 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them
US5739333A (en) 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
CN1102580C (zh) * 1995-12-20 2003-03-05 山之内制药株式会社 芳基乙烯基磺酰胺衍生物及其医药组合物
TWI284642B (en) 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
US6417360B1 (en) 1999-03-03 2002-07-09 Hoffmann-La Roche Inc. Heterocyclic sulfonamides

Also Published As

Publication number Publication date
US20030220359A1 (en) 2003-11-27
US6951856B2 (en) 2005-10-04
KR100826332B1 (ko) 2008-05-02
DE60120711T2 (de) 2007-06-06
IL153471A0 (en) 2003-07-06
NO20030274D0 (no) 2003-01-20
HUP0300965A3 (en) 2004-01-28
AU2001281970B2 (en) 2006-03-16
CA2416785A1 (en) 2002-01-31
CN1441788A (zh) 2003-09-10
TWI289553B (en) 2007-11-11
CA2416785C (en) 2009-11-10
IL153471A (en) 2007-09-20
ZA200300137B (en) 2004-04-06
ES2266233T3 (es) 2007-03-01
KR20030016382A (ko) 2003-02-26
BR0112614A (pt) 2003-06-10
WO2002008200A3 (en) 2002-05-10
ATE329908T1 (de) 2006-07-15
EP1309564B1 (en) 2006-06-14
EP1309564A2 (en) 2003-05-14
AU8197001A (en) 2002-02-05
AR030247A1 (es) 2003-08-13
JP4832706B2 (ja) 2011-12-07
JP2004504385A (ja) 2004-02-12
MY140724A (en) 2010-01-15
WO2002008200A2 (en) 2002-01-31
MXPA03000430A (es) 2003-06-24
NO20030274L (no) 2003-01-20
DE60120711D1 (de) 2006-07-27
NZ523304A (en) 2005-02-25
CN100562518C (zh) 2009-11-25
NO324771B1 (no) 2007-12-10

Similar Documents

Publication Publication Date Title
HUP0300965A2 (hu) Új aril-etén-szulfonamidok pirimidinszármazékai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE206611T1 (de) Verwendung von mangiferin oder seinen derivaten zur kosmetischen anwendung
MY127537A (en) Novel amidine deirvatives,their preparation and applicantion as medicines and pharmaceutical compositions
WO2004013101A3 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
CA2113229A1 (en) Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof
HUP9802578A2 (hu) Fenil-ecetsav-származékok, eljárás és intermedierek előállításukhoz, a vegyületeket hatóanyagként tartalmazó fungicid, inszekticid, arachnicid és nematocid készítmények és alkalmazásuk
BG103399A (en) New heterocycle-substituted benzamides and their application for the treatment of diseases
HUP9801599A2 (hu) Alfa1L-agonista imidazolinszármazékok alkalmazása inkontinencia kezelésére szolgáló gyógyszerkészítmények előállítására, új imidazolin-származékok és eljárás ezek előállítására
BR9610960A (pt) Derivados de 8-azabiciclo [3.2.1] oct -2- eno sua preparação e uso
MX9605741A (es) Clorhidrato cristalino del (r)-(-)-2-{n-[4-(1,1-dioxido-3-oxo-2,3-dihidro-benzisotiazol-2-il)-butil ]-aminometil} cromano.
HUT75053A (en) Insecticidal n-(substituted arylmethyl)-4-[bis(substituted phenyl)methyl]piperidines, insecticid composition and use of it
AP9901462A0 (en) Stable non-hygroscopic crystalline form of N-[N-N-(4-(Piperidin-4-YL)Butanoyl)-N-Ethylglycyl] amide.
HUP0303364A2 (hu) Endotelin-antagonista aktivítású aril-alkán-szulfonamidok pirimidinszármazékai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ES2154830T3 (es) Derivados de 2-aminolactama n-(4-bencilo sustituida).
HUP0300298A2 (hu) 4-[Piperazinil-8-(kinolinil-metil)]benzamid-származékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
ES8609277A1 (es) Procedimiento para la obtencion de 1-(bis-(4-fluorofenil)- metil)-4-(3-fenil-2-propenil)-hexahidro-1h-1, 4-diacepina
IL120984A0 (en) Salts of ethyl 3-(2-(4-(4-(amino-imino-methyl)phenyl)-4-methyl-2,5-dioxoimidazolidin-1-YL)acetylamino) 3-phenylpropionate their preparation and pharmaceutical compositions containing them
BR9508676A (pt) Carbamolicarboxamida composição processos para preparar compostos e a composição e para controlar fungos nocivos e uso compost e das composições
MY136928A (en) New isoquinoline compounds, a process for their preparation and pharmaceutical composition containing them
ES2196090T3 (es) Derivados pirimidinicos.
HUP0105111A1 (hu) 2,5-Helyettesített benzolszulfonilkarbamid- és tiokarbamidszármazékok, eljárás előállításukra, alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
RU95102147A (ru) Производные 1-[2-(1н-инден-3-ил)этил]-4-(нафт-1-ил)пиперазина, способ их получения и содержащие их медикамент и фармацевтический состав
HUP0203476A2 (en) Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate, use thereof and pharmaceutical composition containing the same
RU94028266A (ru) Бициклические производные имидазола, метод их получения, новые полученные промежуточные продукты, их применение в качестве медикаментов и содержащие их фармацевтические соединения
IL66937A (en) N-(3-trimethylstannylalkylene)-n&#39;-phenylsulfonyl or benzoyl urea derivatives,their preparation and insecticidal compositions containing them

Legal Events

Date Code Title Description
FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): DR. JALSOVSZKY GYOERGYNE UEGYVED, HU

Representative=s name: DANUBIA SZABADALMI ES JOGI IRODA KFT., HU

FH92 Termination of representative

Representative=s name: DR. JALSOVSZKY GYOERGYNE UEGYVED, HU

FD9A Lapse of provisional protection due to non-payment of fees